{
  "docId": "019f6b8e-d87d-74a8-98e5-6fc840cf4742",
  "docSlug": "jarvis-10-ibd-presentation-2012-taro-pharmaceutical-industries-citigroup",
  "documentTitle": "10 IBD presentation 2012 Taro Pharmaceutical Industries Citigroup",
  "authorId": "10-ibd-presentation-2012-taro-pharmaceutical-industries-citigroup",
  "authorName": null,
  "documentKindSlug": "deck",
  "documentKindLabel": "Deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2012-01-01 00:00:00",
  "orientation": null,
  "aspectRatio": null,
  "pageNumber": 7,
  "pageCount": 27,
  "prevPage": 6,
  "nextPage": 8,
  "slideType": "other",
  "function": "analyze_data",
  "density": "balanced",
  "nDataPoints": 45,
  "notes": "The slide highlights the lack of analyst coverage and low float (34%) resulting in low trading volume for Taro Pharma.",
  "elementsJson": null,
  "metadataConfidence": 0.95,
  "imagePath": null,
  "slideHref": "/slides/019f6b8e-d87d-74a8-98e5-6fc840cf4742/7",
  "deckHref": "/decks/019f6b8e-d87d-74a8-98e5-6fc840cf4742",
  "deckJsonHref": "/decks/019f6b8e-d87d-74a8-98e5-6fc840cf4742.json",
  "deckAnchorHref": "/decks/019f6b8e-d87d-74a8-98e5-6fc840cf4742#slide-7",
  "components": [
    {
      "bbox": {
        "h": 0.3,
        "w": 0.85,
        "x": 0.07,
        "y": 0.15
      },
      "kind": "list",
      "text": "Taro is currently not covered by any equity research houses. Sun Pharma provides limited disclosure. Taro issues a quarterly press release but no guidance. Sun Pharma consolidates financials. Only 34% of Taro's shares trade on the NYSE.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d1c52fc5-2af8-4ff0-b250-03175edcdb55",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.75,
        "x": 0.13,
        "y": 0.45
      },
      "kind": "table",
      "text": "Comparison of 3M, 6M, and 12M ADTV as % Float for Taro Pharma vs. peers and market segments.",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fc6c7a6e-4182-4036-b8e4-0c06781759bf",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.4,
        "x": 0.07,
        "y": 0.08
      },
      "kind": "title",
      "text": "Taro Trading Perspectives",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b1856759-8faf-45de-8cbe-1b4b2475c5a4",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 8,
      "from": 6,
      "beatId": "bf50e422-96a9-446c-90f1-ef787140617a",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Market Size",
      "beatSlug": "sequoia-pitch-market-size",
      "evidence": "The document provides context for Taro's financial performance",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}